PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today presented its consolidated financial results for the fiscal year ended December 31, 2008.
